Traynor Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Traynor Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,000	Closed	-$12.2K	–	368
2025 Q2	$12.2K	Buy	+11,000	New	+$12.3K	﹤0.01%	258

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Traynor Capital Management's BCLI Position: Q3 2025 in Review

Traynor Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 11,000 shares — an estimated $12.2K sold.

Traynor Capital Management first reported a position in BCLI in Q2 2025 and held it in 1 quarter. The position peaked at $12.2K in Q2 2025. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Traynor Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Traynor Capital Management sold 11,000 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $12.2K.
Traynor Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2025 and held it in 1 quarter.
Traynor Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $12.2K in Q2 2025.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Traynor Capital Management's 13F filing for Q3 2025, filed 3 Nov 2025.